10 results on '"Jöhrens, Korinna"'
Search Results
2. MSI testing: What’s new? What should be considered?
- Author
-
Rüschoff, Josef, Baretton, Gustavo, Bläker, Hendrik, Dietmaier, Wolfgang, Dietel, Manfred, Hartmann, Arndt, Horn, Lars-Christian, Jöhrens, Korinna, Kirchner, Thomas, Knüchel, Ruth, Mayr, Doris, Merkelbach-Bruse, Sabine, Schildhaus, Hans-Ulrich, Schirmacher, Peter, Tiemann, Markus, Tiemann, Katharina, Weichert, Wilko, and Büttner, Reinhard
- Published
- 2021
- Full Text
- View/download PDF
3. MSI-Testung: Was ist neu? Was ist zu beachten?
- Author
-
Rüschoff, Josef, Baretton, Gustavo, Bläker, Hendrik, Dietmaier, Wolfgang, Dietel, Manfred, Hartmann, Arndt, Horn, Lars-Christian, Jöhrens, Korinna, Kirchner, Thomas, Knüchel, Ruth, Mayr, Doris, Merkelbach-Bruse, Sabine, Schildhaus, Hans-Ulrich, Schirmacher, Peter, Tiemann, Markus, Tiemann, Katharina, Weichert, Wilko, and Büttner, Reinhard
- Published
- 2021
- Full Text
- View/download PDF
4. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
- Author
-
Rupp, Luise, Resag, Antonia, Potkrajcic, Vlatko, Warm, Verena, Wehner, Rebekka, Jöhrens, Korinna, Bösmüller, Hans, Eckert, Franziska, and Schmitz, Marc
- Subjects
T cells ,SARCOMA ,T helper cells ,COMBINED modality therapy ,PROGNOSIS - Abstract
Soft tissue sarcomas (STS) form a heterogeneous group of tumors sharing a mesenchymal origin. Despite good local control of the disease, the occurrence of distant metastases often limits survival of STS patients with localized, high-risk tumors of the extremities. Accumulating evidence suggests a central role for the tumor immune microenvironment in determining the clinical outcome and response to therapy. Thus, it has been reported that STS patients with a high immune signature and especially presence of B cells and tertiary lymphoid structures display improved overall survival and response to checkpoint inhibitor treatment. Here, we explored the effect of curative multimodal therapy on the T cell landscape of STS using multiplex immunohistochemistry. We analyzed the phenotype, frequency, and spatial distribution of STS-infiltrating CD8
+ T cells by staining for CD8, 4-1BB, Granzyme B, Ki67, PD-1, and LAG-3 as well as CD3+ T helper cells using a panel consisting of CD3, T-bet, GATA3, RORγT, FoxP3, and Ki67. All patients received neoadjuvant radiotherapy plus locoregional hyperthermia with or without chemotherapy. While the treatment-naïve biopsy sample allows an analysis of baseline T cell infiltration levels, both intra- and peritumoral areas of the matched resected tissue were analyzed to assess composition and spatial distribution of the T cell compartment and its therapeutic modulation. Generally, post-treatment tissues displayed lower frequencies of CD3+ and CD8+ T cells. Association with clinical data revealed that higher post-treatment frequencies of peritumoral and intratumoral CD3+ T cells and intratumoral PD-1+ CD8+ T cells were significantly associated with improved disease-free survival (DFS), while these densities had no prognostic significance in the biopsy. Upon spatial analysis, a high ratio of intratumoral to peritumoral CD8+ T cells emerged as an independent prognostic marker for longer DFS. These results indicate that the STS T cell landscape is altered by multimodal therapy and may influence the clinical outcome of patients. An enhanced understanding of the STS immune architecture and its modulation by neoadjuvant therapy may pave the way towards novel treatment modalities and improve the long-term clinical outcome of STS patients. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma
- Author
-
Rüder, Ulrike, Denkert, Carsten, Alisa Kunze, Catarina, Jank, Paul, Lindner, Judith, Jöhrens, Korinna, Kulbe, Hagen, Sehouli, Jalid, Dietel, Manfred, Braicu, Elena, and Darb Esfahani, Silvia
- Subjects
Ovarian ,6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología [CDU] ,High-grade serous carcinoma ,APOBEC3B ,Prognosis - Abstract
APOBEC3 enzymes are part of the innate immune system and they are important in retroviral defense. The number of mutations in ovarian cancer increases with rising levels of APOBEC3B mRNA. We could confirm that APOBEC3B mRNA is upregulated in ovarian cancer cell lines and in ovarian cancer tissue. We evaluated APOBEC3B expression in histologically defined subtypes of ovarian cancer to identify its influence on overall survival (OS) and progression-free survival (PFS). Tissue microarrays from 219 patients with highgrade serous (HGSC), 61 with low-grade serous (LGSC), 62 with endometrioid (EC) and 55 with clear cell (CCC) ovarian carcinoma were stained using an antibody against APOBEC3B. Real-time quantitative PCR was performed to detect APOBEC3B mRNA levels in 274 cases of HGSC, in 11 cases of LGSC, in 47 cases of EC and in 29 cases of CCC. Tumor-infiltrating lymphocytes (TILs) have been evaluated in a previous project. APOBEC3B staining was cytoplasmic as well as nuclear and both were positively correlated (P
- Published
- 2019
6. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.
- Author
-
Kasajima, Atsuko, Sers, Christine, Sasano, Hironobu, Jöhrens, Korinna, Stenzinger, Albrecht, Noske, Aurelia, Buckendahl, Ann-Christin, Darb-Esfahani, Silvia, Müller, Berit Maria, Budczies, Jan, Lehman, Annika, Dietel, Manfred, Denkert, Carsten, and Weichert, Wilko
- Subjects
COLON cancer ,ANTIGENS ,INFLAMMATION ,CANCER prognosis ,MAJOR histocompatibility complex ,IMMUNOHISTOCHEMISTRY ,CANCER immunology - Abstract
Summary: Antitumor inflammatory response is known to inhibit tumor growth in colorectal carcinoma. The density and functionality of tumor-infiltrating lymphocytes (TIL) is regulated by the antigen processing machinery through regulator proteins such as transporters associated with antigen processing (TAP) and major histocompatibility complex (MHC) class I antigen. We aimed to investigate the in vivo association of those factors and their impact on prognosis in colorectal cancer. TAP1, TAP2 and MHC class I antigen expression, inflammatory infiltrate and TIL (CD4
+ , CD8+ , and CD20+ ) were assessed by immunohistochemistry in 336 sporadic colorectal carcinomas. The factors were correlated with each other and with clinic-pathological parameters and patient outcome. We found TAP1 and TAP2 expression to be significantly associated with MHC class I antigen expression (TAP1: r = 0.363, P < .001; TAP2: r = 0.393, P < .001). Increased density of CD8+ TIL was predominantly found in TAP1, TAP2 and MHC class I antigen–positive cases. Increased density of CD4+ TIL was linked with TAP1 and TAP2, but not with MHC class I antigen. High CD4+ and CD8+ cell count but not TAP1, TAP2 and MHC class I antigen expression had favorable prognostic impact in colorectal cancer (P = .003 and P = .003, respectively). In conclusion, our data show that the expression of key components of the antigen processing machinery is tightly linked to the density of TIL, which are positive prognostic factors in colorectal cancer in vivo. This implies that modulation of these factors may help to enhance antitumor inflammatory response which in turn may improve patient prognosis. [Copyright &y& Elsevier]- Published
- 2010
- Full Text
- View/download PDF
7. Prognostic Significance of Estrogen Receptor Alpha in Oral Squamous Cell Carcinoma.
- Author
-
Doll, Christian, Bestendonk, Carolin, Kreutzer, Kilian, Neumann, Konrad, Pohrt, Anne, Trzpis, Irena, Koerdt, Steffen, Dommerich, Steffen, Heiland, Max, Raguse, Jan-Dirk, and Jöhrens, Korinna
- Subjects
MOUTH tumors ,HEAD & neck cancer ,ESTROGEN receptors ,SQUAMOUS cell carcinoma - Abstract
Simple Summary: Although the survival rate has improved over the past decades, the prognosis of oral squamous cell carcinoma (OSCC) is still poor, and new treatment strategies are required. The aim of this study was to evaluate estrogen receptor alpha (ERα) expression in OSCC in a large patient cohort as a potential prognostic marker and therapeutic target. The findings indicated a rare expression of ERα that, however, was associated with a dramatic decrease of overall survival in male patients. In ERα-positive OSCC patients, an ER-based therapeutic (adjuvant) approach in the future might be conceivable based on the findings of this study. Introduction: Several studies suggest an estrogen receptor alpha (ERα)-mediated influence on the pathogenesis of oral squamous cell carcinoma (OSCC), as described for other malignancies that are not considered to be primarily hormone-dependent. Recently, an association between ERα expression and improved survival in oropharyngeal squamous cell carcinoma (OPSCC) has been found. However, the prognostic relevance of ERα in OSCC has not been proven to date. Therefore, the aim of this study was to evaluate ERα expression in OSCC in a large patient cohort and analyze its influence on survival and recurrence. Material and Methods: A total of 316 patients with primary OSCC who received initial surgical therapy were included in this analysis. The expression of ERα was evaluated on tissue microarrays by immunohistochemistry in the primary tumor and/or primary lymph node metastases. The expression level was quantified by light microscopy using the immunoreactive score (IRS) for estrogen receptor detection. An IRS equal to or greater than 2 was considered positive. The 5-year overall survival (OS) and relapse-free survival (RFS) were examined by the Kaplan–Meier method and log-rank test. Results: A total of 316 patients (111 females; 205 males) with a mean age of 61.3 years (range 27–96 years) were included in this study. In 16 patients (5.1%; 6 females and 10 males), positive ERα expression was found in the primary tumor (n = 11; 11/302) or lymph node metastases (n = 5; 5/52). Patients with positive ERα expression in primary tumors/primary lymph node metastases had a significantly lower OS and RFS (p = 0.012; p = 0.0053) compared to ERα-negative patients. Sub-group analysis in relation to gender revealed a highly significant influence of ERα expression on OS and RFS in males but not in females, both for the ERα-positive primary tumor cohort (males: p = 0.0013; p < 0.0001; females: p = 0.56; p = 0.89) and the ERα-positive primary tumor/primary lymph node metastasis cohort (males: p < 0.0001; p < 0.0001; females: p = 0.95; p = 0.96). In multivariate cox regression analysis, the ERα IRS of primary tumors (dichotomized; ERα+ vs. ERα−) was an independent risk factor for OS (HR = 4.230; 95%CI 1.616–11.076; p = 0.003) and RFS (HR = 12.390; 95%CI 4.073–37.693; p < 0.001) in the male cohort. There was a significant difference (p = 0.006) of ERα positivity with regard to the localization of the primary tumor. ERα positivity in the primary tumor was significantly associated (p = 0.026) with UICC stage, with most of the cases being diagnosed in stage IV. Furthermore, there was a significantly (p = 0.049) higher rate of bone infiltration in ERα-positive patients. Conclusion: Expression of ERα is rare in OSCC; however, it is associated with a dramatic decrease in OS in male patients. Further studies are necessary to confirm our results and to evaluate the exact mechanism underlying this observation. Hence, ERα-positive OSCC patients might benefit from an ER-based therapeutic (adjuvant) approach in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Molecular subtyping of head and neck cancer – Clinical applicability and correlations with morphological characteristics.
- Author
-
Stögbauer, Fabian, Otto, Raik, Jöhrens, Korinna, Tinhofer, Ingeborg, Keilholz, Ulrich, Poremba, Christopher, Keller, Ulrich, Leser, Ulf, Weichert, Wilko, Boxberg, Melanie, and Klinghammer, Konrad
- Subjects
- *
HEAD & neck cancer , *TUMOR budding , *HEMATOXYLIN & eosin staining , *PROGNOSIS , *GENE expression , *SQUAMOUS cell carcinoma - Abstract
• Analysis of recurrent/metastatic head and neck cancer. • Feasibility of a 231-gene NanoString panel in determining the molecular subtypes. • Tumor budding prognostically significant in recurrent/metastatic state. We aimed to evaluate the applicability of a customized NanoString panel for molecular subtyping of recurrent or metastatic head and neck squamous cell carcinoma (R/M−HNSCC). Additionally, histological analyses were conducted, correlated with the molecular subtypes and tested for their prognostic value. We conducted molecular subtyping of R/M−HNSCC according to the molecular subtypes defined by Keck et al. For molecular analyses a 231 gene customized NanoString panel (the most accurately subtype defining genes, based on previous analyses) was applied to tumor samples from R/M−HNSCC patients that were treated in the CeFCiD trial (AIO/IAG-KHT trial 1108). A total of 130 samples from 95 patients were available for sequencing, of which 80 samples from 67 patients passed quality controls and were included in histological analyses. H&E stained slides were evaluated regarding distinct morphological patterns (e.g. tumor budding, nuclear size, stroma content). Determination of molecular subtypes led to classification of tumor samples as basal (n = 46, 45 %), inflamed/mesenchymal (n = 31, 30 %) and classical (n = 26, 25 %). Expression levels of Amphiregulin (AREG) were significantly higher for the basal and classical subtypes compared to the mesenchymal subtype. While molecular subtypes did not have an impact on survival, high levels of tumor budding were associated with poor outcomes. No correlation was found between molecular subtypes and histological characteristics. Utilizing the 231-gene NanoString panel we were able to determine the molecular subtype of R/M−HNSCC samples by the use of FFPE material. The value to stratify for different treatment options remains to be explored in the future. The prognostic value of tumor budding was underscored in this clinically well annotated cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Dissecting the spatial heterogeneity of different immune cell subsets in non-small cell lung cancer.
- Author
-
Jurmeister, Philipp, von Laffert, Maximilian, and Jöhrens, Korinna
- Subjects
- *
NON-small-cell lung carcinoma , *INTRA-aortic balloon counterpulsation , *T cell differentiation , *PROGNOSIS , *B cells - Abstract
To date, most studies investigating the immune tumor microenvironment of non-small cell lung cancers (NSCLC) only consider a small number of immune cell subsets or do not reflect the distribution of these cells between different tumor compartments as they were performed on tissue microarrays (TMA). To address this, we analyzed the immune infiltrate in surgically resected NSCLCs, focusing on potential spatial heterogeneity. We evaluated 45 NSCLCs based on whole-slide sections using immunohistochemistry with eleven different antibodies (CD3, CD4, CD8, CD20, CD68, Gata3, FOXP3, T-bet, kappa, lambda, PD-L1). While most markers were relatively evenly distributed among different tumor compartments as well as within the same tumor compartment, some immune cell subsets showed a considerable variance. Notably, the immune infiltrate at the tumor invasion front was dominated by B cells. Concerning markers for T cell differentiation, FoxP3 (Th2) was predominantly expressed in stromal lymphocytes, while T-bet (Th1) was most commonly expressed in intraepithelial immune cells. Although most immune cell subtypes showed a heterogenous distribution within in the intraepithelial compartment, the results from a simulated TMA and core biopsy were mostly in line with the results from whole slide evaluation. Regarding disease specific survival, there were no clear correlations. Interestingly, patients with intraepithelial T-bet positive lymphocytes had a significantly better outcome (p = 0.039), however, this difference was not preserved in multivariate analysis. In conclusion, our study shows that the immune tumor microenvironment of NSCLCs is complex and partially heterogenous, especially concerning markers for T cell differentiation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
- Author
-
Lohneis, Philipp, Sinn, Marianne, Bischoff, Sven, Jühling, Anja, Pelzer, Uwe, Wislocka, Lilianna, Bahra, Marcus, Sinn, Bruno V., Denkert, Carsten, Oettle, Helmut, Bläker, Hendrik, Riess, Hanno, Jöhrens, Korinna, and Striefler, Jana K.
- Subjects
- *
ADENOCARCINOMA , *ANTIMETABOLITES , *IMMUNOHISTOCHEMISTRY , *PANCREATIC tumors , *PROGNOSIS , *SURVIVAL , *T cells , *DUCTAL carcinoma , *TISSUE arrays , *DESCRIPTIVE statistics - Abstract
Background We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study. Methods Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures. Results A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population. Median DFS/OS were 7.4/18.1 months for patients with a low number of CD8-positive intratumoural lymphocytes ( ≤ 42 per 1 mm tissue core) and 12.7/25.2 months for patients with high numbers (>42 per 1-mm tissue core; p = 0.008/0.020; HR 0.62/0.65). The ratio of intraepithelial to total CD103-positive lymphocytes, but not total numbers of CD103-positive lymphocytes or CD103-positive intraepithelial lymphocytes, was associated with significantly improved DFS and OS in the overall study population (p = 0.022/0.009). Median DFS/OS was 5.9/15.7 for patients with a ratio of intraepithelial to total CD103-positive intratumoural lymphocytes higher than 0.3 and 11.6/24.7 for patients with a lower ratio. Conclusion T-lymphocyte subpopulations might be prognostic in resectable PDAC but need standardization and verification by further studies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.